{
    "clinical_study": {
        "@rank": "43661", 
        "arm_group": [
            {
                "arm_group_label": "No AKI", 
                "description": "Patients with cirrhosis admitted to hospital with bacterial infection with initial serum creatinine below 1.5mg/dL."
            }, 
            {
                "arm_group_label": "AKI and Infection", 
                "description": "Patients with cirrhosis admitted to hospital with bacterial infection and initial serum creatinine above 1.5mg/dL."
            }, 
            {
                "arm_group_label": "AKI with No Infection", 
                "description": "Patients with cirrhosis admitted to hospital with initial serum creatinine above 1.5mg/dL without bacterial infection."
            }
        ], 
        "biospec_descr": {
            "textblock": "We will store samples of urine and serum frozen at -80oC."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the accuracy of urinary neutrophil-gelatinase\n      associated lipocalin (NGAL) and other biomarkers (plasma renin, norepinephrine) to predict\n      acute kidney injury (AKI) development in patients with cirrhosis and bacterial infection and\n      to predict response to AKI treatment with albumin and albumin with terlipressin in patients\n      with suspected hepatorenal syndrome."
        }, 
        "brief_title": "Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Kidney Injury", 
            "Hepatorenal Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatorenal Syndrome", 
                "Acute Kidney Injury", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cirrhosis diagnosis by liver biopsy or combination of clinical, laboratorial,\n             endoscopic and imagenological data;\n\n          -  Presence of ascites and/or hepatic hydrothorax;\n\n          -  Age over 18 years old;\n\n          -  Diagnosis of bacterial infection (including spontaneous bacterial peritonitis and\n             others) with or without acute kidney injury (defined as a serum creatinine above\n             1.5mg/dL  at admission) or acute kidney injury without bacterial infection;\n\n          -  Agreement to participate in the study, registered by informed consent;\n\n        Exclusion Criteria:\n\n          -  Serious comorbidities (functional class IV heart failure, O2 dependent chronic\n             obstructive pulmonary disease, advanced cancer);\n\n          -  Shock, as defined by American College of Chest Physicians;\n\n          -  Chronic kidney disease with serum creatinine persistently above 1.5mg/dL in the\n             previous 6 months and/or with sonographic findings of chronic nephropathy;\n\n          -  Intrinsic nephropathy with hematuria over 50 red cells/high power field and\n             dysmorphic erythrocyte and/or proteinuria over 500mg/24h;\n\n          -  Use of nephrotoxic drugs in the previous 30 days;\n\n          -  Dialysis prior to study inclusion;\n\n          -  Previous solid organ transplantation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "We will include cirrhotic patients admitted to hospitals participating centers with AKI\n        and/or bacterial infection."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02049125", 
            "org_study_id": "NGAL01"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NGAL", 
            "Acute kidney injury", 
            "Cirrhosis", 
            "Hepatorenal syndrome"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "lucianalofego@terra.com.br", 
                    "last_name": "Luciana L Goncalves, Ph. D."
                }, 
                "facility": {
                    "address": {
                        "city": "Vitoria", 
                        "country": "Brazil", 
                        "state": "Espirito Santo", 
                        "zip": "29075-910"
                    }, 
                    "name": "Federal University of Espirito Santo"
                }, 
                "investigator": {
                    "last_name": "Luciana L Goncalves, Ph. D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "andradem@medicina.ufmg.br", 
                    "last_name": "Marcus Vinicius M Andrade, Prof. Assoc."
                }, 
                "facility": {
                    "address": {
                        "city": "Belo Horizonte", 
                        "country": "Brazil", 
                        "state": "Minas Gerais", 
                        "zip": "30130-100"
                    }, 
                    "name": "Federal University of Minas Gerais"
                }, 
                "investigator": {
                    "last_name": "Marcus Vinicius M Andrade, Prof. Assoc.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "marioreis@live.com", 
                    "last_name": "Mario RA Silva, Assoc. Prof."
                }, 
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "Rio Grande do Sul", 
                        "zip": "90035-903"
                    }, 
                    "name": "Federal University of Rio Grande do Sul"
                }, 
                "investigator": {
                    "last_name": "Mario RA Silva, Assoc. Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rximenes@gmail.com", 
                    "last_name": "Rafael O Ximenes, MD", 
                    "phone": "+55011 2661-3338"
                }, 
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "zip": "05403-010"
                    }, 
                    "name": "University of Sao Paulo"
                }, 
                "investigator": [
                    {
                        "last_name": "Alberto Q Farias, Assoc. Prof.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ana LC Martinelli, Assoc. Prof.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Flair J Carrilho, Professor", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "carolinapimentel.gastro@gmail.com", 
                    "last_name": "Carolina Pimentel, MD", 
                    "phone": "+55011 99653-9040"
                }, 
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "zip": "04024002"
                    }, 
                    "name": "Federal University of Sao Paulo"
                }, 
                "investigator": {
                    "last_name": "Aecio Flavio T Gois, Ph. D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_groups": "3", 
        "official_title": "Urinary Biomarker NGAL in Decompensated Cirrhosis: Early Prediction of AKI and of Treatment Response", 
        "overall_contact": {
            "email": "rximenes@gmail.com", 
            "last_name": "Rafael O Ximenes, MD", 
            "phone": "+55 011 2661-3338"
        }, 
        "overall_official": {
            "affiliation": "University of Sao Paulo", 
            "last_name": "Alberto Q Farias, Associate professor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will build a receiver-operating curve and calculate the area under the curve to determine the accuracy of NGAL to predict no response to albumin expansion. No response will be defined as an absence of a drop of serum creatinine to a final value below 1.5mg/dL in the day after the end of albumin expansion. Albumin will be administrated as International Ascites Club recommendations, i.e. in the dose of 1g/kg/day for 2 days in patients with suspected hepatorenal syndrome.", 
            "measure": "Accuracy of NGAL to predict no response to albumin expansion", 
            "safety_issue": "No", 
            "time_frame": "One day after albumin expansion (day 3)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02049125"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Sao Paulo", 
            "investigator_full_name": "Alberto Queiroz Farias", 
            "investigator_title": "Associate Professor of Medicine School of University of Sao Paulo", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "We will test the accuracy of urinary NGAL and other biomarkers to predict no response to hepatorenal syndrome treatment. No response to treatment will be defined as a final value of serum creatinine above 1.5mg/dL after the end of treatment with terlipressin plus albumin. The treatment will be conducted according to International Ascites Club recommendations.", 
                "measure": "Accuracy of urinary NGAL and other biomarkers to predict no response to hepatorenal syndrome treatment", 
                "safety_issue": "No", 
                "time_frame": "Treatment period (maximum of 14 days)"
            }, 
            {
                "description": "We will test the accuracy of urinary NGAL and other biomarkers to predict AKI development in the next five days and during hospital stay in patients with serum creatinine below 1.5mg/dL at admission. AKI will be defined as a raise in serum creatinine of at least 50% to a final value above 1.5mg/dL. We will also test other definitions of AKI, particularly AKIN and KDIGO.", 
                "measure": "Accuracy of urinary NGAL and other biomarkers to predict development of acute kidney injury (AKI)", 
                "safety_issue": "No", 
                "time_frame": "Day 5 and during hospital stay"
            }, 
            {
                "description": "We will test clinical and laboratorial data relationship with in-hospital, 30 days and 90 days mortality in a univariate analysis. Associated variables will be tested in a multivariate analysis.", 
                "measure": "Predictors of mortality", 
                "safety_issue": "No", 
                "time_frame": "In-hospital, 30 days and 90 days"
            }, 
            {
                "description": "We will build a receiver-operating curve and calculate the area under the curve to determine the accuracy of urinary NGAL to predict adverse events during AKI treatment with albumin alone or in combination with terlipressin. We will also calculate the best cut-off value based on the receiver-operating curve.", 
                "measure": "Urinary NGAL as a predictor of adverse events of AKI treatment in cirrhosis", 
                "safety_issue": "Yes", 
                "time_frame": "During treatment period"
            }, 
            {
                "description": "We will test the accuracy of other biomarkers to predict no response to albumin expansion. No response will be defined as an absence of a drop of serum creatinine to a final value below 1.5mg/dL in the day after the end of albumin expansion. Albumin will be administrated as International Ascites Club recommendations, i.e. in the dose of 1g/kg/day for 2 days in patients with suspected hepatorenal syndrome.", 
                "measure": "Accuracy of other biomarkers to predict no response to albumin expansion", 
                "safety_issue": "No", 
                "time_frame": "One day after albumin expansion (day 3)"
            }
        ], 
        "source": "University of Sao Paulo", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Federal University of S\u00e3o Paulo", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Federal University of Rio Grande do Sul", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Federal University of Minas Gerais", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Federal University of Espirito Santo", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Sao Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}